China
Maohua Wang, head of the IP group at King & Wood Mallesons in China, explains how the firm’s Eversheds deal affected the IP team and how his team meets clients’ litigation needs
Loeb & Loeb has taken on the IP, corporate and compliance teams from Perkins Coie’s soon-to-be closed Beijing office
In-house counsel believe Chinese domestic firms are becoming as sophisticated as international firms, but they may not shift their portfolios just yet
Tom Treutler, who previously managed the Vietnamese office of Tilleke & Gibbins, has joined East IP
Sponsored
Sponsored
-
Sponsored by Liu Shen & AssociatesDanchen Cheng of Liu Shen & Associates discusses the consequences of China’s amended patent law for partial design patent applications -
Sponsored by Purplevine IPXiaoyan Zhou of Purplevine IP analyses the Fifth Set of Listing Standards for Medical Device Companies on STAR Market of the Shanghai Stock Exchange, which encourages companies to develop core technologies
-
Sponsored by Wanhuida Intellectual PropertyYue Guan of Wanhuida Intellectual Property analyses a decision by the China National Intellectual Property Administration on the validity of a pulmonary hypertension drug and the implications for pharmaceutical patentees
-
Sponsored by Purplevine IPXiaoyan Zhou of Purplevine IP explains how the introduction of administrative measures for registering, and filing records relating to, medical devices in China should affect companies’ IP strategy
-
Sponsored by Liu Shen & AssociatesGuanyang Yao, Yali Shao and Yuan Zhang of Liu Shen & Associates provide a practical insight into the 4th amended Patent Law in China
-
Sponsored by Wanhuida Intellectual PropertyJianhui Li and Honghui Hu of Wanhuida Intellectual Property discuss the antitrust scrutiny of China’s Supreme People’s Court in a patent infringement appeal concerning reverse payment settlement agreement
